Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

NCT04524208 is registered in ClinicalTrials.gov with Karsten Gavenis as lead sponsor.

NCT NCT04524208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
Lead sponsor
Karsten Gavenis
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2021
Completion date
October 31, 2024
Enrollment
45 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine carcinoma, neuroendocrine tumors